ArticleAdvances in therapy2019

Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.

Haijing Guan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.